Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic). The study, involving over 17,600 participants, showed a statistically meaningful, though relatively small, increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Understanding the SELECT Trial: key Details
The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. Participants did not have diabetes. They were randomly assigned to receive either 2.4 mg of semaglutide weekly or a placebo, in addition to their standard care. The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. The median follow-up period was 3.95 years.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.1% | 1.74 (1.11 to 2.73) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.33 (0.83 to 2.13) |
| Nonfatal Stroke | 3.7% | 2.4% | 1.54 (0.94 to 2.52) |
| Unstable Angina Requiring Hospitalization | 1.2% | 0.8% | 1.49 (0.74 to 2.99) |
| Composite Cardiovascular Outcome | 9.6% | 7.9% | 1.25 (1.00 to 1.56) |
What Does This Mean? Beyond the Numbers
The observed increase in cardiovascular events, while statistically significant, is crucial to contextualize. The absolute risk difference was relatively small – approximately 1.7% over nearly four years. However, for individuals already at high cardiovascular risk, even a small increase is clinically meaningful. The trial results suggest that semaglutide may not be universally cardioprotective, and its use in this specific population requires careful consideration.
